AN2 Therapeutics, Inc.

NASDAQ:ANTX

1.25 (USD) • At close January 15, 2025
Bedrijfsnaam AN2 Therapeutics, Inc.
Symbool ANTX
Munteenheid USD
Prijs 1.255
Beurswaarde 37,498,007
Dividendpercentage 0%
52-weken bereik 0.87 - 21.55
Industrie Biotechnology
Sector Healthcare
CEO Mr. Eric E. Easom
Website https://www.an2therapeutics.com

An error occurred while fetching data.

Over AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Vergelijkbare Aandelen

Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc.

TNYA

1.47 USD

ESSA Pharma Inc. logo

ESSA Pharma Inc.

EPIX

1.76 USD

AC Immune SA logo

AC Immune SA

ACIU

2.68 USD

Precigen, Inc. logo

Precigen, Inc.

PGEN

1.13 USD

Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc.

DYN

15.54 USD

Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc.

LXRX

0.728 USD

Alpine Immune Sciences, Inc. logo

Alpine Immune Sciences, Inc.

ALPN

64.97 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)